– USA, MA – C4 Therapeutics, Inc. (Nasdaq: CCCC), a clinical-stage biopharmaceutical company today announced the appointment of Utpal Koppikar to its board of directors.
Mr. Koppikar will also join the Audit Committee as Chair and the Organization, Leadership, and Compensation Committee as a member.
About Utpal Koppikar
Utpal Koppikar is CFO of Atara Biotherapeutics Inc., a leader in T-cell immunotherapy. In addition, C4T announced that Dr. Elena Prokupets has retired from the board of directors, and a search is underway to further diversify the board.
Mr. Koppikar commented, “The potential of targeted protein degradation to make a transformative impact on patients is tremendously exciting and I am honored to be joining C4T’s board of directors as the Company advances multiple programs through the clinic and invests in its next wave of oncology targets. I look forward to working with my fellow board members and C4T’s leadership team as the company extends its leadership in the targeted protein degradation field.”
Mr. Koppikar currently serves as CFO of Atara Biotherapeutics, where he is responsible for leading the finance, information technology, and investor relations functions as well as guiding the company’s strategy as a member of the senior leadership team. Previously, Mr. Koppikar was VP of operations finance at Gilead Sciences, Inc. where he led the financial integration of Kite Pharma and played an integral role in pricing committees. Mr. Koppikar began his career in life sciences at Amgen, Inc., where he held multiple positions of increasing seniority, ultimately serving as executive director of financial planning and analysis. Mr. Koppikar previously served as a board member of Flexion Therapeutics Inc. until its sale to Pacira BioSciences, Inc. in November 2021.
Mr. Koppikar earned a B.S. in aerospace engineering from the University of Maryland, an M.S. in aeronautical engineering from Stanford University, and an MBA in finance from UCLA’s Anderson School of Management.
About C4 Therapeutics
C4 Therapeutics is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transform patients’ lives. C4T is leveraging its TORPEDO® platform to efficiently design and optimize small-molecule medicines that harness the body’s natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, drug undruggable targets and improve patient outcomes. C4T is advancing multiple targeted oncology programs to the clinic and expanding its research platform to deliver the next wave of medicines for difficult-to-treat diseases.
For more information: https://c4therapeutics.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.